Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

Correction to: International Journal of Clinical Oncology 10.1007/s10147-022-02232-7

In the original publication in Table 1, the entry: “Nichirei Histofine RALK iAEP Kit” should read as: “Nichirei Histofine ALK iAEP Kit”. The correct version of Table 1 is given in this correction.

Table 1.

Baseline patient characteristics

Characteristic	TKI-naive cohort n = 32
Age, median (range), y	60.5 (29–85)
Sex, male, n (%)	15 (47)
ECOG performance status, n (%)
0	16 (50)
1	15 (47)
2	1 (3)
Smoking history, n (%)
Never smoked	20 (63)
Former smoker	12 (38)
Current smoker	0 (0)
Stage of disease, n (%)
IIIB	0 (0)
IV	32 (100)
Histopathological type of NSCLC, n (%)
Adenocarcinoma	30 (93.8)
Adenosquamous carcinoma	1 (3.1)
Suspected adenocarcinoma	1 (3.1)
Brain metastases at baseline, n (%)	7 (22)
Time from initial diagnosis to treatment, median (range), mo	1 (0.3–232)
Methods for ALK rearrangement assessmenta, n (%)
FISH-Vysis	1 (3)
Vysis ALK break apart FISH Probe Kit	13 (41)
Nichirei Histofine ALK iAEP Kit	20 (63)
Ventana ALK (D5F3) CDx Assay	10 (31)
RT-PCR	0 (0.0)
Sequencing	0 (0.0)
Other	3 (9)
Detected fusion partner on ALK, n (%)
EML4	3 (9)
Unknown	29 (91)
Prior chemotherapy, n (%)	8 (25)
Prior radiotherapy, n (%)	6 (19)
Prior brain radiotherapy, n (%)	3 (9)

ALK anaplastic lymphoma kinase; ECOG Eastern Cooperative Oncology Group; EML4 echinoderm microtubule-associated protein-like 4; FISH fluorescence in situ hybridization; iAEP intercalated antibody-enhanced polymer; NSCLC non-small cell lung cancer; RT–PCR reverse transcription polymerase chain reaction; TKI tyrosine kinase inhibitor

^aPatients could have more than one documentation of ALK rearrangement detected by different methods

The original publication has been corrected.